MEXICO CITY

JUNE 22 – 24, 2017

GLOBAL EXPERTS, LOCAL LEARNING

ACC Latin America Conference 2017

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

Spencer B. King III MD MACC

Emeritus Professor of Medicine
Emory University School of Medicine
The Andreas Gruentzig Cardiovascular Center
Editor-in-Chief: JACC Cardiovascular Interventions

CoreValve SURTAVI Trial Clinical Sites

The clinical outcomes in 1746 intermediate-risk patients with severe, symptomatic aortic stenosis were investigated in a randomized fashion comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement.



Up to 115 worldwide centers in Europe, Canada, and United States

TRIAL Timeline

ACC Latin America Conference 2017

The NEW ENGLAND JOURNAL of MEDICINE

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

M.J. Reardon, N.M. Van Mieghem, J.J. Popma, N.S. Kleiman, L. Søndergaard, M. Mumtaz, D.H. Adams, G.M. Deeb, B. Maini, H. Gada, S. Chetcuti, T. Gleason, J. Heiser, R. Lange, W. Merhi, J.K. Oh, P.S. Olsen, N. Piazza, M. Williams, S. Windecker, S.J. Yakubov, E. Grube, R. Makkar, J.S. Lee, J. Conte, E. Vang, H. Nguyen, Y. Chang, A.S. Mugglin, P.W.J.C. Serruys, and A.P. Kappetein, for the SURTAVI Investigators*

N Engl J Med 2017;376:1321-31

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

The clinical outcomes in 1746 intermediate-risk patients with severe, symptomatic aortic stenosis were investigated in a randomized fashion comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement.

The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement.



N Engl J Med 2017;376:1321-31

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

The clinical outcomes in 1746 intermediate-risk patients with severe, symptomatic aortic stenosis were investigated in a randomized fashion comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement.

The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement.



N Engl J Med 2017;376:1321-31

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

The clinical outcomes in 1746 intermediate-risk patients with severe, symptomatic aortic stenosis were investigated in a randomized fashion comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement.

The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement.



N Engl J Med 2017;376:1321-31

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients

The clinical outcomes in 1746 intermediate-risk patients with severe, symptomatic aortic stenosis were investigated in a randomized fashion comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement.

The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement.

Disabling Stroke

	24-Mo Rate (%)		
	TAVR	Surgery	95% CI for difference
	2.6	4.5	–4.0 to 0.1



Conclusion:

TAVR was a noninferior alternative to surgery in patients with severe aortic steno- sis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure.

N Engl J Med 2017;376:1321-31

CoreValve US Pivotal Trial
High Risk Study

795 patients between surgical aortic valve replacement (SAVR) and TAVI with the CoreValve System across 45 US sites.

Superior Long-Term Clinical Outcomes

Lower Rate of Mortality or Stroke with CoreValve than with SAVR.



All-Cause Mortality at 30 Days

Edwards SAPIEN Valves (As Treated Patients)

THE PARTNER TRIAL

PARTNER I and II Trials
Overall and TF Patients



Thank you